Personalized Medicine Bioinformatics Market Report 2026

The personalized medicine bioinformatics market size has grown rapidly in recent years. It will grow from $3.87 billion in 2025 to $4.4 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to expansion of next-generation sequencing usage, growing availability of genomic datasets, increasing research funding in precision medicine, rising demand for data-driven clinical insights, advances in bioinformatics algorithms.

The personalized medicine bioinformatics market size is expected to see rapid growth in the next few years. It will grow to $7.23 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing integration of bioinformatics in clinical workflows, rising investments in personalized medicine programs, expansion of ai-enabled clinical decision support, growing adoption of population-scale genomics analysis, increasing demand for interoperable health data platforms. Major trends in the forecast period include increasing adoption of AI-driven genomic data analytics, rising use of multi-omics data integration platforms, growing demand for cloud-based bioinformatics solutions, expansion of pharmacogenomic decision support tools, enhanced focus on scalable data interpretation frameworks.

The growing demand for personalized medicine is expected to drive the growth of the personalized medicine bioinformatics market going forward. Advances in genomics and analytics enable precise treatment planning. Personalized medicine bioinformatics processes genomic data to guide treatment selection and drug response prediction. For instance, FDA approvals for personalized treatments increased in 2023. Therefore, rising demand for personalized medicine is supporting market growth.

Leading companies operating in the personalized medicine bioinformatics market are focusing on developing advanced solutions such as predictive analytics platforms to enhance disease prediction and improve patient outcomes. A predictive analytics platform uses machine learning, algorithms, and statistical models to analyze historical and real-time data to forecast outcomes, enabling healthcare providers to anticipate risks, optimize treatments, and make proactive clinical decisions. For instance, in April 2023, Certis Oncology Solutions, a US-based biotechnology company, launched CertisAI, a predictive analytics platform. This AI- and machine learning-based platform applies big data, statistical algorithms, and advanced analytics to predict drug efficacy based on gene expression biomarkers, with the objective of accelerating drug discovery and companion diagnostics development in precision oncology. The platform is validating its proprietary methodology for predicting therapeutic response and supporting its deployment as a service for biopharmaceutical companies to improve early drug development decisions and personalized cancer treatment strategies.

In May 2025, GeneDx Holdings Corp., a US-based provider of genomic testing and diagnostic services, acquired Fabric Genomics for up to $51 million. Through this acquisition, GeneDx aims to enhance its decentralized, AI-powered genomic interpretation capabilities to support rapid and scalable genomic diagnostics. Fabric Genomics is a US-based provider of AI-driven genomic interpretation software specializing in whole-genome sequencing analysis.

Major companies operating in the personalized medicine bioinformatics market are F. Hoffmann-La Roche AG, Merck KGaA Darmstadt Germany, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., Guardant Health Inc., Sophia Genetics SA, DNAnexus Inc., Deep Genomics Inc., Congenica Ltd, Phase Genomics Inc., Analome Inc., Pluto Bioinformatics Inc., BioBam Bioinformatics S.L., OncoBox Inc.

North America was the largest region in the personalized medicine bioinformatics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine bioinformatics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized medicine bioinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the personalized medicine bioinformatics market by increasing costs of imported high-performance computing hardware, data storage systems, sequencing accessories, and advanced software licenses. Biotechnology and pharmaceutical companies in North America and Europe are most affected due to reliance on imported computational infrastructure, while Asia-Pacific faces higher costs for bioinformatics platform deployment. These tariffs are increasing implementation costs and slowing infrastructure expansion. However, they are also encouraging domestic development of bioinformatics software, regional cloud infrastructure investments, and localized data analytics capabilities.

The personalized medicine bioinformatics market research report is one of a series of new reports that provides personalized medicine bioinformatics market statistics, including personalized medicine bioinformatics industry global market size, regional shares, competitors with a personalized medicine bioinformatics market share, detailed personalized medicine bioinformatics market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine bioinformatics industry. This personalized medicine bioinformatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Personalized medicine bioinformatics refers to an applied field that combines advanced computational technologies with biological data to examine individual genetic and molecular profiles. It supports accurate interpretation of complex biological information to enable informed clinical decision-making. PMB improves the precision of medical insights and speeds the identification of patient-specific treatment strategies. Its key strength lies in providing data-driven clarity to understand individual biological variation.

The primary technology types of personalized medicine bioinformatics are gene sequencing, pharmacogenomics, microarray technology, artificial intelligence-driven analytics platforms, and others. Gene sequencing involves determining the precise nucleotide sequence of DNA or RNA to analyze genetic variations affecting individual responses to therapies. Applications include genomics, proteomics, transcriptomics, metabolomics, epigenomics, and others and serve end-users such as biotechnology and pharmaceutical companies, clinical diagnostic laboratories, hospitals and academic medical centers, contract research organizations, biobanks, and others.

The personalized medicine bioinformatics market consists of revenues earned by entities by providing services next-generation sequencing (NGS), interpretation, variant annotation, and multi-omics data integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized medicine bioinformatics market also includes sales of genomic analysis software, variant interpretation and annotation tools, clinical decision support systems, and bioinformatics data management and workflow tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.